399 related articles for article (PubMed ID: 19396167)
1. Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis.
King JC; Xu J; Wongvipat J; Hieronymus H; Carver BS; Leung DH; Taylor BS; Sander C; Cardiff RD; Couto SS; Gerald WL; Sawyers CL
Nat Genet; 2009 May; 41(5):524-6. PubMed ID: 19396167
[TBL] [Abstract][Full Text] [Related]
2. Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer.
Furusato B; Gao CL; Ravindranath L; Chen Y; Cullen J; McLeod DG; Dobi A; Srivastava S; Petrovics G; Sesterhenn IA
Mod Pathol; 2008 Feb; 21(2):67-75. PubMed ID: 18065961
[TBL] [Abstract][Full Text] [Related]
3. Role of the TMPRSS2-ERG gene fusion in prostate cancer.
Tomlins SA; Laxman B; Varambally S; Cao X; Yu J; Helgeson BE; Cao Q; Prensner JR; Rubin MA; Shah RB; Mehra R; Chinnaiyan AM
Neoplasia; 2008 Feb; 10(2):177-88. PubMed ID: 18283340
[TBL] [Abstract][Full Text] [Related]
4. TMPRSS2- driven ERG expression in vivo increases self-renewal and maintains expression in a castration resistant subpopulation.
Casey OM; Fang L; Hynes PG; Abou-Kheir WG; Martin PL; Tillman HS; Petrovics G; Awwad HO; Ward Y; Lake R; Zhang L; Kelly K
PLoS One; 2012; 7(7):e41668. PubMed ID: 22860005
[TBL] [Abstract][Full Text] [Related]
5. Characterization of stage-specific tumor progression in TMPRSS2-ERG (fusion)-driven and non-fusion-driven prostate cancer in GEM models.
Raina K; Kant R; Prasad RR; Kandhari K; Tomar M; Mishra N; Kumar R; Fox JT; Sei S; Shoemaker RH; Chen Y; Maroni P; Agarwal C; Agarwal R
Mol Carcinog; 2022 Jul; 61(7):717-734. PubMed ID: 35452553
[TBL] [Abstract][Full Text] [Related]
6. Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications.
Mosquera JM; Perner S; Genega EM; Sanda M; Hofer MD; Mertz KD; Paris PL; Simko J; Bismar TA; Ayala G; Shah RB; Loda M; Rubin MA
Clin Cancer Res; 2008 Jun; 14(11):3380-5. PubMed ID: 18519767
[TBL] [Abstract][Full Text] [Related]
7. Antibody-based detection of ERG rearrangements in prostate core biopsies, including diagnostically challenging cases: ERG staining in prostate core biopsies.
Tomlins SA; Palanisamy N; Siddiqui J; Chinnaiyan AM; Kunju LP
Arch Pathol Lab Med; 2012 Aug; 136(8):935-46. PubMed ID: 22849743
[TBL] [Abstract][Full Text] [Related]
8. Effect of nonsteroidal anti-inflammatory drugs (aspirin and naproxen) on inflammation-associated proteomic profiles in mouse plasma and prostate during TMPRSS2-ERG (fusion)-driven prostate carcinogenesis.
Prasad RR; Mishra N; Kant R; Fox JT; Shoemaker RH; Agarwal C; Raina K; Agarwal R
Mol Carcinog; 2024 Jun; 63(6):1188-1204. PubMed ID: 38506376
[TBL] [Abstract][Full Text] [Related]
9. Protocols for Studies on TMPRSS2/ERG in Prostate Cancer.
Pakula H; Linn DE; Schmidt DR; Van Gorsel M; Vander Heiden MG; Li Z
Methods Mol Biol; 2018; 1786():131-151. PubMed ID: 29786791
[TBL] [Abstract][Full Text] [Related]
10. Concurrent TMPRSS2-ERG and SLC45A3-ERG rearrangements plus PTEN loss are not found in low grade prostate cancer and define an aggressive tumor subset.
Hernández S; Font-Tello A; Juanpere N; de Muga S; Lorenzo M; Salido M; Fumadó L; Serrano L; Cecchini L; Serrano S; Lloreta J
Prostate; 2016 Jun; 76(9):854-65. PubMed ID: 26959281
[TBL] [Abstract][Full Text] [Related]
11. Genetic interaction between Tmprss2-ERG gene fusion and Nkx3.1-loss does not enhance prostate tumorigenesis in mouse models.
Linn DE; Bronson RT; Li Z
PLoS One; 2015; 10(3):e0120628. PubMed ID: 25780911
[TBL] [Abstract][Full Text] [Related]
12. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate.
Carver BS; Tran J; Gopalan A; Chen Z; Shaikh S; Carracedo A; Alimonti A; Nardella C; Varmeh S; Scardino PT; Cordon-Cardo C; Gerald W; Pandolfi PP
Nat Genet; 2009 May; 41(5):619-24. PubMed ID: 19396168
[TBL] [Abstract][Full Text] [Related]
13. ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells.
Zong Y; Xin L; Goldstein AS; Lawson DA; Teitell MA; Witte ON
Proc Natl Acad Sci U S A; 2009 Jul; 106(30):12465-70. PubMed ID: 19592505
[TBL] [Abstract][Full Text] [Related]
14. Antibody-based detection of ERG rearrangement-positive prostate cancer.
Park K; Tomlins SA; Mudaliar KM; Chiu YL; Esgueva R; Mehra R; Suleman K; Varambally S; Brenner JC; MacDonald T; Srivastava A; Tewari AK; Sathyanarayana U; Nagy D; Pestano G; Kunju LP; Demichelis F; Chinnaiyan AM; Rubin MA
Neoplasia; 2010 Jul; 12(7):590-8. PubMed ID: 20651988
[TBL] [Abstract][Full Text] [Related]
15. Infiltration of Prostate Cancer by CD204+ and CD3+ Cells Correlates with ERG Expression and TMPRSS2-ERG Gene Fusion.
Burdova A; Rulisek P; Bouchal J; Král M; Student V; Kolar Z
Klin Onkol; 2018; 31(6):421-428. PubMed ID: 30545222
[TBL] [Abstract][Full Text] [Related]
16. Altered PCA3 and TMPRSS2-ERG expression in histologically benign regions of cancerous prostates: a systematic, quantitative mRNA analysis in five prostates.
Väänänen RM; Ochoa NT; Boström PJ; Taimen P; Pettersson K
BMC Urol; 2015 Aug; 15():88. PubMed ID: 26294063
[TBL] [Abstract][Full Text] [Related]
17. ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification.
Furusato B; Tan SH; Young D; Dobi A; Sun C; Mohamed AA; Thangapazham R; Chen Y; McMaster G; Sreenath T; Petrovics G; McLeod DG; Srivastava S; Sesterhenn IA
Prostate Cancer Prostatic Dis; 2010 Sep; 13(3):228-37. PubMed ID: 20585344
[TBL] [Abstract][Full Text] [Related]
18. TMPRSS2:ERG gene fusion predicts subsequent detection of prostate cancer in patients with high-grade prostatic intraepithelial neoplasia.
Park K; Dalton JT; Narayanan R; Barbieri CE; Hancock ML; Bostwick DG; Steiner MS; Rubin MA
J Clin Oncol; 2014 Jan; 32(3):206-11. PubMed ID: 24297949
[TBL] [Abstract][Full Text] [Related]
19. Molecular evidence that invasive adenocarcinoma can mimic prostatic intraepithelial neoplasia (PIN) and intraductal carcinoma through retrograde glandular colonization.
Haffner MC; Weier C; Xu MM; Vaghasia A; Gürel B; Gümüşkaya B; Esopi DM; Fedor H; Tan HL; Kulac I; Hicks J; Isaacs WB; Lotan TL; Nelson WG; Yegnasubramanian S; De Marzo AM
J Pathol; 2016 Jan; 238(1):31-41. PubMed ID: 26331372
[TBL] [Abstract][Full Text] [Related]
20. Clinical applications of novel ERG immunohistochemistry in prostate cancer diagnosis and management.
Shah RB
Adv Anat Pathol; 2013 Mar; 20(2):117-24. PubMed ID: 23399797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
